Clinical Trial

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 1, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-12-04; most recent amendment 2024-10-30.
Status change: Not Yet Recruiting → Recruiting 2024-02-25
Trial Details
NCT Number NCT06167681
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Parkinson Disease
Enrollment 40 participants
Start Date 2024-01-17
Primary Completion 2025-12 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2024-11-01